CXCL9 and neoplasm: The relationship between the CXCL9,10,11-CXCR3 pathway and PD-1/PD-L1 was found to be an essential area of research during the study of immunotherapy in colorectal cancer (131), and combining this pathway with other immunotherapies improves the efficacy of tumor immunotherapy by enhancing the inhibitory effect on tumor development through multiple mechanisms.